The novel regulatory role of lncRNA‐miRNAmRNA axis in cardiovascular diseases

Journal of Cellular and Molecular Medicine - Tập 22 Số 12 - Trang 5768-5775 - 2018
Ying Huang1
1Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Tóm tắt

Abstract

Long noncoding RNAs (lncRNAs) are RNAs longer than 200 nt in length that are characterized by low levels of sequence conservation and expression; lncRNAs modulate various biological functions at epigenetic, transcriptional and post‐transcriptional levels, or directly regulate protein activity. As a family of small and evolutionarily conserved noncoding RNAs, microRNAs (miRNAs) are capable of regulating physiological and pathological processes via inhibiting target mRNA translation or promoting mRNA degradation. A number of studies have confirmed that both lncRNAs and miRNAs are closely associated with the development of cardiovascular diseases (CVDs), such as cardiac remodelling, heart failure, myocardial injury and arrhythmia, and that they act as biomarkers, potential therapeutic targets or strong indicators of prognosis; however, the underlying molecular mechanism has not been elucidated. Recently, emerging evidence showed that the novel regulatory mechanism underlying the crosstalk among lncRNAs, miRNAs and mRNAs plays a pivotal role in the pathophysiological processes of CVDs in response to stress stimuli. In this review, I comprehensively summarized the regulatory relationship of lncRNAs, miRNAs and mRNAs and highlighted the important role of the lncRNA‐miRNAmRNA axis in CVDs.

Từ khóa


Tài liệu tham khảo

10.1161/CIRCRESAHA.117.308903

10.1016/j.cell.2013.01.003

10.1126/scitranslmed.aai9118

10.7150/thno.16478

10.1038/cdd.2014.165

10.1016/j.jacc.2016.07.739

10.1152/physrev.00041.2015

10.1038/nrcardio.2014.125

10.1038/nrg.2015.10

10.1038/nm.4179

10.1016/j.cell.2010.09.001

10.1186/1476-4598-11-5

10.1159/000374006

10.1172/JCI83361

10.1093/eurheartj/ehx165

10.1016/j.cmet.2015.02.014

10.1161/CIRCRESAHA.117.310624

10.15252/emmm.201506031

10.1038/s41467-017-00304-1

10.1093/nar/gkw1247

10.1016/j.canlet.2017.08.015

10.1161/CIRCRESAHA.114.302476

10.18632/oncotarget.8413

10.1038/cdd.2013.110

10.1016/j.bbrc.2017.09.036

10.1111/jcmm.12755

Zhu XH, 2016, LncRNA MIAT enhances cardiac hypertrophy partly through sponging miR‐150, Eur Rev Med Pharmacol Sci, 20, 3653

10.1101/gad.1658508

10.1038/ncomms4596

10.1371/journal.pgen.1004467

10.1016/j.bbrc.2004.07.178

10.1186/s13578-016-0123-5

10.1038/nature06639

10.1038/ncomms7779

10.1007/s10059-010-0066-3

10.1161/CIRCRESAHA.117.305781

10.1038/cdd.2016.28

10.1016/j.tox.2017.05.007

10.1161/CIRCRESAHA.112.300849

10.1242/jcs.114.8.1447

10.1161/ATVBAHA.114.304296

10.1016/j.molcel.2013.08.027

10.1038/ncb2521

10.1093/cvr/cvw078

10.1111/jpi.12331

10.1016/j.febslet.2015.08.046

10.1016/j.devcel.2013.03.002

10.1038/cddis.2014.249

10.1038/cddiscovery.2017.4

10.1371/journal.pone.0152767

10.1038/nm1582

Kotecha D, 2015, Atrial fibrillation in heart failure: what should we do?, Eur Heart J, 36, 3250

10.3892/mmr.2016.5893

10.1016/j.yjmcc.2016.08.012

10.1016/j.yjmcc.2017.05.009

10.1161/CIRCRESAHA.116.305510

10.1038/cddis.2016.145

10.18632/oncotarget.16850

10.1016/j.biopha.2017.06.089

10.1038/srep30921

10.1093/cvr/cvw201

10.1016/j.jacc.2015.12.051